Millrace Asset Group Inc. Has $286,000 Stock Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Millrace Asset Group Inc. trimmed its holdings in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 76.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,940 shares of the company's stock after selling 22,820 shares during the period. Millrace Asset Group Inc.'s holdings in Inari Medical were worth $286,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Bessemer Group Inc. boosted its position in shares of Inari Medical by 16.4% in the first quarter. Bessemer Group Inc. now owns 2,439 shares of the company's stock worth $117,000 after acquiring an additional 344 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Inari Medical by 7.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company's stock valued at $234,000 after buying an additional 348 shares during the period. Arizona State Retirement System increased its holdings in shares of Inari Medical by 2.5% during the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company's stock worth $703,000 after buying an additional 358 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock worth $46,000 after purchasing an additional 435 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company's stock worth $34,000 after purchasing an additional 438 shares during the period. Hedge funds and other institutional investors own 90.98% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NARI. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research note on Friday, August 9th. They set a "buy" rating and a $68.00 price objective for the company. Stifel Nicolaus started coverage on Inari Medical in a research note on Tuesday, September 17th. They set a "hold" rating and a $50.00 price objective for the company. Leerink Partnrs raised shares of Inari Medical to a "hold" rating in a research report on Tuesday, September 3rd. Canaccord Genuity Group increased their price target on shares of Inari Medical from $71.00 to $74.00 and gave the stock a "buy" rating in a research report on Tuesday, October 29th. Finally, Leerink Partners assumed coverage on Inari Medical in a research note on Tuesday, September 3rd. They issued a "market perform" rating and a $47.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Inari Medical presently has a consensus rating of "Hold" and a consensus target price of $58.89.

Inari Medical Trading Up 2.7 %

NASDAQ NARI traded up $1.35 during trading hours on Tuesday, reaching $50.83. The company's stock had a trading volume of 1,022,949 shares, compared to its average volume of 985,291. The business has a 50-day simple moving average of $45.73 and a 200 day simple moving average of $47.38. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $67.13. The stock has a market cap of $2.98 billion, a PE ratio of -36.93 and a beta of 0.96.

Insider Buying and Selling

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the company's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the transaction, the director now owns 601,233 shares in the company, valued at approximately $27,067,509.66. This represents a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the sale, the chief executive officer now directly owns 445,310 shares in the company, valued at approximately $22,265,500. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 186,000 shares of company stock valued at $8,990,990. Insiders own 10.60% of the company's stock.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.